SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (4938)11/29/1997 6:43:00 PM
From: Robert K.  Read Replies (2) | Respond to of 17367
 
Ok so far. Now this trial is in itself a trial of bpis potential in this area. If it works for partial liver, it might work for other liver problems or even other surgerys (insults). Consider cirrohis or hepatitis. Now those are big markets. Will it work in partial hep.-We dont know. Will it work in cirrohsis or hepatitis. We really dont know. The significance is what if it does. Does that help?



To: aknahow who wrote (4938)11/29/1997 9:48:00 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
Neisseria meningitidis is the bacteria, and meningococcemia is the specific clinical picture.

A DNA probe test will detect the DNA of the bacteria.

It does not matter the specific clinical condition, if the bacteria DNA is found you got it. Probably has to do with PCR probes, they are fast and specific.

Both terms and its equivalents are used in dutch (my guess).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News